Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Lannett Stock Is Soaring Today

By Maxx Chatsko – Updated Aug 28, 2019 at 11:54AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The generic drug manufacturer announced fiscal 2019 results and inked an important supply deal.

What happened

Shares of Lannett Company (LCI 4.04%) rose as much as 46.8% today after the company made several announcements. First, the generic drug specialist said it would advise Cediprof on how best to proceed with efforts to commercialize generic drug products in the United States. The deal has the potential to provide services revenue and deepen the pair's working relationship, which could land Lannett lucrative manufacturing, supply, and distribution deals. 

Second, the business announced it had entered into a new agreement to become the exclusive U.S. distributor of posaconazole delayed-release tablets, an antifungal medication, from Sinotherapeutics of China. Third, Lannett Company announced fiscal full-year 2019 operating results that exceeded expectations and provided fiscal full-year 2020 guidance far ahead of what Wall Street was expecting. 

As of 12:23 p.m. EDT on Wednesday, the stock had settled to a 39.6% gain.

A businessman riding a cartoon rocket.

Image source: Getty Images.

So what

Today's news items are significant for Lannett, especially in light of the volatility and uncertainty that has gripped the stock in the last two years following the loss of its former top customer

The advisory deal with Cediprof may not yield much in terms of direct services revenue, but it could make Lannett the partner of choice as Cediprof looks to expand its presence in the U.S. generics market. Lannett is currently the supply and distribution partner for Cediprof's levothyroxine sodium tablets. 

The exclusive distribution deal with Sinotherapeutics for posaconazole tablets will have a more direct impact on operations. The innovator drug brand, Noxafil from Merck, generated $325 million in U.S. revenue in the 12-month period ending June 30. The generic drug brands resulting from Lannett's manufacturing and distribution will launch into a less lucrative market opportunity (generic drugs sell for lower prices and have to compete with the trust of the innovator brand), but capturing even 10% of the market represents a significant growth opportunity. 

Meanwhile, Lannett reported $655 million in revenue for fiscal 2019, which eclipsed the most recent expectations calling for $645 million at best. The results are significantly better than the expectations from six months ago, when management expected no more than $635 million in full-year revenue. The company currently expects $535 million in fiscal full-year 2020 revenue, easily topping the average estimate on Wall Street of just $506 million, according to numbers compiled by Yahoo! Finance

Now what

While shares of Lannett Company have fallen 75% in the last three years, investors have to be pleased with management's efforts to outgrow the uncertainty. It will still take time to replace the former top customer (the most recent quarter was the first without it), but the business appears to be headed in the right direction. That said, it may be best to wait for further signs of progress before investing in the stock.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Lannett Company, Inc. Stock Quote
Lannett Company, Inc.
$0.47 (4.04%) $0.02
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$86.78 (1.09%) $0.94

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.